首页> Vaccine> Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.

导出原文传递

翻译打印收藏纠错

第一作者： Brandon,Essink

第一单位： Meridian Clinical Research, Creighton, NE, USA. Electronic address: bessink@mcrmed.com.

作者： Brandon,Essink ^[1] ; Carlos,Fierro ^[2] ; Jeffrey,Rosen ^[3] ; Amparo L,Figueroa ^[4] ; Bin,Zhang ^[5] ; Carole,Verhoeven ^[6] ; Jonathan,Edelman ^[7] ; Igor,Smolenov ^[8]

作者单位： Meridian Clinical Research, Creighton, NE, USA. Electronic address: bessink@mcrmed.com. ^[1] Johnson County Clin Trials, Lenexa, KS, USA. Electronic address: cfierro@jcct.com. ^[2] Alliance of MultiSpeciality Research, Coral Gables, FL, USA. Electronic address: Jeffrey.Rosen@amrllc.com. ^[3] Clinical Vaccines, Seqirus Inc., Cambridge, MA, USA. Electronic address: amparo.figueroa@seqirus.com. ^[4] Clinical Vaccines, Seqirus Inc., Cambridge, MA, USA. Electronic address: bin.zhang@seqirus.com. ^[5] Seqirus Netherlands BV, Amsterdam, the Netherlands. Electronic address: Carole.Verhoeven@Seqirus.com. ^[6] Clinical Vaccines, Seqirus Inc., Cambridge, MA, USA. Electronic address: Jonathan.edelman@seqirus.com. ^[7] Clinical Vaccines, Seqirus Inc., Cambridge, MA, USA. Electronic address: Igor.Smolenov@Seqirus.com. ^[8]

关键词 Adjuvanted quadrivalent influenza vaccine Adjuvanted trivalent influenza vaccine Elderly Fluad Influenza vaccine MF59